ClinicalTrials.gg
CompletedNCT07722273Updated Oct 13, 2026

Immediate Effects of Pogo Jumps on Vertical Jump Performance in Young Basketball Players

An interventional study of POGO-JUMP and CONTROL in Post-activation Performance Enhancement, sponsored by Cardenal Herrera University. Completed at 1 site in Spain. Open to male participants aged 15 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Cardenal Herrera University · Not applicable, Interventional, and Other

Updated Oct 13, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
15 Years to 18 Years
Sex
Male
01

Study summary

This study aims to examine the acute effects of a low-volume bilateral pogo jump protocol on CMJ and DJ performance, as well as its feasibility and immediate tolerance in adolescent male basketball players.

Read the detailed description

This study aims to investigate whether a low-volume bilateral pogo jump protocol can induce post-activation performance enhancement (PAPE) in adolescent male basketball players. Using a randomized crossover design, participants will complete both a pogo jump intervention and a light walking control condition, with countermovement jump (CMJ) and drop jump (DJ) performance assessed before and one minute after each condition. The study will also evaluate the immediate tolerance and field feasibility of this microdose plyometric protocol.

02

Conditions studied

  • Post-activation Performance Enhancement

Keywords

  • Post-activation performance enhancement
  • plyometric exercise
  • pogo jumps
  • countermovement jump
  • basketball
  • drop jump
03

In context

Lead sponsor

Cardenal Herrera University is the lead sponsor of 108 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Regular structured basketball training.
  • Ability to understand instructions.
  • Safe execution of the jump tests after familiarization.
  • Written from a parent or legal guardian, and assent from the minor.

Exclusion criteria

Exclusion Criteria:

  • Acute injury limiting participation.
  • Lower-limb pain aggravated by jumping.
  • Recent surgery or a relevant health condition.
  • Inability to perform the test technique safely.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    POGO-JUMP

    Participants will perform 3 sets of 8 consecutive bilateral pogo jumps (24 ground contacts in total), with 1 min of passive recovery between sets. They will be instructed to jump with maximal intent, minimize ground contact time, and maintain relative knee extension while avoiding a deep countermovement.

    Other: POGO-JUMP

  • Active comparator
    CONTROL

    Participants will walk continuously at a comfortable, low intensity for approximately 3 min, without running, jumping, or abrupt changes of pace. The duration will be selected to approximate that of the experimental condition.

    Other: CONTROL

Interventions

  • OtherPOGO-JUMP

    Participants will perform 3 sets of 8 consecutive bilateral pogo jumps (24 ground contacts in total), with 1 min of passive recovery between sets. They will be instructed to jump with maximal intent, minimize ground contact time, and maintain relative knee extension while avoiding a deep countermovement.

  • OtherCONTROL

    Participants will walk continuously at a comfortable, low intensity for approximately 3 min, without running, jumping, or abrupt changes of pace.

06

What researchers measure

Primary outcomes

  1. Countermovement jump (CMJ) height (cm)

    Participants will stand upright with their hands on their hips and perform a self-selected countermovement followed immediately by a maximal vertical jump. Jump height (cm) will be calculated from flight time recorded using the Chronojump Boscosystem contact platform.

    Time frame: Baseline and immediately after the intervention

  2. Drop jump (DJ) height (cm)

    Participants will step off an 18 cm box, land with both feet simultaneously, and immediately perform a maximal vertical jump while minimizing ground contact time. Jump height (cm) will be calculated from flight time recorded using the Chronojump Boscosystem contact platform.

    Time frame: Baseline and immediately after the intervention

07

Study locations

1 site
  • University Cardenal Herrera
    Alfara del Patriarca, Valencia 46115, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Jul 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Jul 21, 2026
Primary completionActual
Jul 28, 2026
CompletionActual
Jul 28, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Completed
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07722273
Responsible party
Juan F. Lisón Párraga, Dr (Professor, Cardenal Herrera University) — Principal investigator
First posted
Jul 23, 2026
Start date
Jul 21, 2026
Primary completion
Jul 28, 2026
Completion
Jul 28, 2026
Last update
Oct 13, 2026

Study contacts

JF Lisón, Dr
principal investigator · CEU Cardenal Herrera University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion